AKTX — Akari Therapeutics Plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1541157 ·
Last close
$5.70
Market Cap
$13.03M
52W High
$29.32
52W Low
$3.02
ADV30
43,339
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,602,000 | -4,807,000 | 38,624,000 | 7,694,000 | 20,029,000 |
| Mar 2026 | 0 | — | -3,628,000 | -14,455,000 | 33,889,000 | 2,768,000 | 19,509,000 |
| Dec 2025 | 0 | — | -3,227,000 | -5,298,000 | 47,892,000 | 5,203,000 | 19,564,000 |
| Sep 2025 | 0 | — | -2,224,000 | -6,400,000 | 45,376,000 | 2,484,000 | 22,689,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,759,000
Investing CF
—
Financing CF
$15,745,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,812,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-31,837,000
Pretax Income TTM
$-32,822,000
Interest Exp TTM
$985,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -12,095,000 | -17,298,000 | 47,892,000 | 19,564,000 | 28,328,000 | -10,568,000 |
| Dec 2024 | 0 | -16,647,000 | -19,791,000 | 50,562,000 | 28,333,000 | 22,229,000 | -12,552,000 |
| Dec 2023 | 0 | -16,806,000 | -10,008,000 | 4,355,000 | 4,584,000 | -229,000 | -16,432,000 |
| Dec 2022 | 0 | -23,088,000 | -17,748,000 | 13,832,000 | 12,041,000 | 1,791,000 | -21,504,000 |
TTM Snapshot
Revenues TTM
$1,000
NetIncome TTM
$-30,960,000
OpCashFlow TTM
—
Assets (Latest)
$38,624,000
Forward EPS
$-8.65
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $7.12 · call volume: 25 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ONCO | Onconetix, Inc. | $13.14M | $3.00 | — |
| ALLR | Allarity Therapeutics, Inc. | $13.38M | $0.84 | — |
| TVRD | Tvardi Therapeutics, Inc. | $13.47M | $1.01 | — |
| SYBX | SYNLOGIC, INC. | $13.47M | $1.10 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $12.57M | $0.86 | — |
News headlines (Yahoo Finance, 1h cache)
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
2026-11-12 21:05 · Yahoo
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
2026-11-11 13:44 · Yahoo
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
2026-10-30 13:05 · Yahoo
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
2026-10-15 13:20 · Yahoo
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
2026-10-13 13:01 · Yahoo
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
2026-10-01 12:25 · Yahoo
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
2026-09-08 13:15 · Yahoo
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-27 13:01 · Yahoo
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
2026-08-18 12:53 · Yahoo
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
2026-08-13 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.